Evidence map›Paper›PMID 39689302›Full record

ArticleJMIR diabetes2024

Exploring Opportunities and Challenges for the Spread, Scale-Up, and Sustainability of mHealth Apps for Self-Management of Patients With Type 2 Diabetes Mellitus in the Netherlands: Citizen Science Approach.

Catharina Margaretha van Leersum, Marloes Bults, Egbert Siebrand, Theodorus Johannes Josef Olthuis, Robin Enya Marije Bekhuis, Annemieke Ariënne Johanneke Konijnendijk, Marjolein Elisabeth Maria den Ouden

Abstract read
In one paragraph

Article in JMIR diabetes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Trust in Medical AI: The Case of mHealth Diabetes Apps.Journal of evaluation in clinical practice · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Catharina Margaretha van LeersumDepartment of Technology, Policy, and Society, Faculty of Behavioural, Management, and Social Sciences, University of Twente, Enschede, Netherlands.ORCID https://orcid.org/0000-0002-1003-0794
Marloes BultsTechnology, Health & Care Research Group, Saxion University of Applied Sciences, Enschede, Netherlands.ORCID https://orcid.org/0000-0002-6142-4574
Egbert SiebrandEthics and Technology Research Group, Saxion University of Applied Sciences, Deventer, Netherlands.ORCID https://orcid.org/0000-0002-6067-4926
Theodorus Johannes Josef OlthuisCare & Technology Research Group, Regional Community College of Twente, Hengelo, Netherlands.ORCID https://orcid.org/0000-0001-7470-0956
Robin Enya Marije BekhuisDepartment of Smartup Innovation, Ziekenhuisgroep Twente, Almelo, Netherlands.ORCID https://orcid.org/0000-0003-4109-0404
Annemieke Ariënne Johanneke KonijnendijkSanteon, Utrecht, Netherlands.ORCID https://orcid.org/0000-0002-0311-2572
Marjolein Elisabeth Maria den OudenTechnology, Health & Care Research Group, Saxion University of Applied Sciences, Enschede, Netherlands.ORCID https://orcid.org/0000-0001-7821-1578

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTechnologies evolve at a breakneck pace, and the success of mobile health (mHealth) for people with type 2 diabetes mellitus (T2DM) depends on whether health care professionals, care management, government regulators, and consumers will adopt the technology as a viable solution to enhance patient self-management.

objectiveIn this study, we explored the challenges of the implementation of mHealth apps in care for patients with T2DM and determined to what extent these challenges complicate the dissemination, limit scale-up, and influence the sustainability of technological interventions for patients with T2DM.

methodsThe nonadoption, abandonment, and challenges to scale-up, spread, and sustainability (NASSS) framework served as the basis for our study. The 7 domains of the NASSS framework were explored with a citizen science approach using questionnaires, semistructured in-depth interviews, and focus groups together with patients with T2DM, care professionals, technology developers, policy officers, and a patient organization.

resultsRegarding the domain "condition," being aware of their condition and changing lifestyle were crucial for patients with T2DM to get to grips with their life. The rapid development of health apps for T2DM was highlighted in the domain "technology." Users should be aware of these apps and know how to use them. The domain "value proposition" included the patient perspective and elaborated on personal values, as well as care professionals who focus on personalized care and pressure on health care. Regarding the "adopters," it is crucial to know who needs to use and introduce the apps. Responsibility, a shared vision, and resistance among care professionals were mentioned as important determinants for "organization." Finally, the domain "wider system" showed the importance of involving multiple institutes, care guidelines, and reimbursements.

conclusionsThis study investigated the implementation of mHealth apps in an early stage of the implementation process. Key stakeholders were involved, who attributed to the possibilities and limitations of the implementation. It is crucial to have a clear vision from an organizational perspective and specific prerequisites for implementation strategies at micro, meso, and macro levels. Essential strategies at the national level include guidelines for regulations, privacy, and security; the integration of mHealth into T2DM care guidelines; and sufficient reimbursement by health insurers.

Indexed as

citizen sciencediabetesdigital healthdigital interventiondigital technologyDMhealth care systemimplementationmHealthmobile appmobile healthself-managementsmartphonetype 1 diabetestype 2 diabetestype 2 diabetes mellitus

Identifiers

PMID39689302
PMCPMC11688593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.